Innostar provides high-standard and high-throughput human clinical research services that fully comply with GCP and GCLP standards, including bioanalysis, biomarker research, human mass balance based on isotope labeling, calculation and analysis of clinical pharmacokinetic parameters, and application and consulting. The businesses range from analytical method research and verification to timely clinical sample analysis, including small molecules, peptides, proteins, antibodies, ADC, nucleic acid molecules and gene and cell therapy drugs. All samples are managed by using Watson LIMS in the whole life cycle. Core team of each project consists of experienced project manager (PM), project science director (PL) and research leader (PI) to ensure the most effective process, science, timeliness and quality control as well as efficient communication with clients and clinical central laboratories.

Isotope labeling and imaging can not only provide information about the ADME behavior of the drug itself in vivo, but also help understand the mechanism of action, disease relationship, pharmacological action and so on, which can greatly increase the confidence of drug transformation from preclinical to clinical.

Drug safety is not only an important factor leading to a failure of drug research and development, but also a main reason for delisting of listed drugs. Traditionally, toxicity test and safety evaluation of drugs are usually completed in preclinical animal trials. Once it is found that a serious toxic reaction of a drug leads to a failure of research and development, it will result in huge economic losses.